127 related articles for article (PubMed ID: 38314724)
1. Everolimus exerts anticancer effects through inhibiting the interaction of matrix metalloproteinase-7 with syndecan-2 in colon cancer cells.
Lee S; Jang B; Hwang J; Lee Y; Cho S; Yang H; Yun JH; Shin DH; Lee W; Oh ES
Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1067-C1079. PubMed ID: 38314724
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-2 cytoplasmic domain up-regulates matrix metalloproteinase-7 expression via the protein kinase Cγ-mediated FAK/ERK signaling pathway in colon cancer.
Jang B; Jung H; Choi S; Lee YH; Lee ST; Oh ES
J Biol Chem; 2017 Sep; 292(39):16321-16332. PubMed ID: 28821612
[TBL] [Abstract][Full Text] [Related]
3. Substituted Syndecan-2-Derived Mimetic Peptides Show Improved Antitumor Activity over the Parent Syndecan-2-Derived Peptide.
Jang B; Kim A; Lee Y; Hwang J; Sung JY; Jang EJ; Kim YN; Yun JH; Han J; Song JJ; Lee W; Oh ES
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682569
[TBL] [Abstract][Full Text] [Related]
4. The matrix metalloproteinase-7 regulates the extracellular shedding of syndecan-2 from colon cancer cells.
Choi S; Kim JY; Park JH; Lee ST; Han IO; Oh ES
Biochem Biophys Res Commun; 2012 Jan; 417(4):1260-4. PubMed ID: 22227189
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine 51 residue of the syndecan-2 extracellular domain is involved in the interaction with and activation of pro-matrix metalloproteinase-7.
Jang B; Yun JH; Choi S; Park J; Shin DH; Lee ST; Lee W; Oh ES
Sci Rep; 2019 Jul; 9(1):10625. PubMed ID: 31337828
[TBL] [Abstract][Full Text] [Related]
6. Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells.
Ryu HY; Lee J; Yang S; Park H; Choi S; Jung KC; Lee ST; Seong JK; Han IO; Oh ES
J Biol Chem; 2009 Dec; 284(51):35692-701. PubMed ID: 19858218
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1α promotes extracellular shedding of syndecan-2 via induction of matrix metalloproteinase-7 expression.
Kwon MJ; Hong E; Choi Y; Kang DH; Oh ES
Biochem Biophys Res Commun; 2014 Apr; 446(2):487-92. PubMed ID: 24613844
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-2 enhances E-cadherin shedding and fibroblast-like morphological changes by inducing MMP-7 expression in colon cancer cells.
Jang B; Jung H; Chung H; Moon BI; Oh ES
Biochem Biophys Res Commun; 2016 Aug; 477(1):47-53. PubMed ID: 27270030
[TBL] [Abstract][Full Text] [Related]
9. The extracellular domain of syndecan-2 regulates the interaction of HCT116 human colon carcinoma cells with fibronectin.
Kwon MJ; Kim Y; Choi Y; Kim SH; Park S; Han I; Kang DH; Oh ES
Biochem Biophys Res Commun; 2013 Feb; 431(3):415-20. PubMed ID: 23333331
[TBL] [Abstract][Full Text] [Related]
10. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration.
Endo K; Takino T; Miyamori H; Kinsen H; Yoshizaki T; Furukawa M; Sato H
J Biol Chem; 2003 Oct; 278(42):40764-70. PubMed ID: 12904296
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.
He K; Zheng X; Li M; Zhang L; Yu J
Oncogene; 2016 Jan; 35(2):148-57. PubMed ID: 25867072
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
[TBL] [Abstract][Full Text] [Related]
14. The heparan sulfate proteoglycan syndecan-1 regulates colon cancer stem cell function via a focal adhesion kinase-Wnt signaling axis.
Kumar Katakam S; Tria V; Sim WC; Yip GW; Molgora S; Karnavas T; Elghonaimy EA; Pelucchi P; Piscitelli E; Ibrahim SA; Zucchi I; Reinbold R; Greve B; Götte M
FEBS J; 2021 Jan; 288(2):486-506. PubMed ID: 32367652
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-7 induces homotypic tumor cell aggregation via proteolytic cleavage of the membrane-bound Kunitz-type inhibitor HAI-1.
Ishikawa T; Kimura Y; Hirano H; Higashi S
J Biol Chem; 2017 Dec; 292(50):20769-20784. PubMed ID: 29046355
[TBL] [Abstract][Full Text] [Related]
16. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
17. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
18.
Jeon JI; Lee KH; Kim JM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769248
[No Abstract] [Full Text] [Related]
19. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
